NICE says no to Merck Serono’s Bavencio in bladder cancerMerck Serono’s Bavencio is the only checkpoint inhibitor to be approved for first-line maintenance treatment of bladder cancer Share XNICE says no to Merck Serono’s Bavencio in bladder cancerhttps://pharmaphorum.com/news/nice-says-no-to-merck-seronos-bavencio-in-bladder-cancer/
Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenancePfizer and partner Merck KGaA now have approval on both sides of the Atlantic for their checkpoint inhibitor Share XMerck, Pfizer get EU nod for Bavencio as bladder cancer maintenancehttps://pharmaphorum.com/news/merck-pfizer-get-eu-nod-for-bavencio-as-bladder-cancer-maintenance/
AZ stakes its claim in immunotherapy with bladder cancer filingAfter looking like it could get left far behind by rivals in immunotherapy, AstraZeneca has made its first filing for PD-L1 Share XAZ stakes its claim in immunotherapy with bladder cancer filinghttps://pharmaphorum.com/news/az-stakes-claim-immunotherapy-bladder-cancer-filing/
